Key result
Intravenous injection of thromboxane synthetase inhibitors OKY 046 and OKY 1580 significantly prolonged the reappearance time of cyclical reduction of coronary blood flow in dogs (p<0.01).
Why the study?
Does thromboxane synthetase inhibition prevent cyclical reduction of coronary blood flow in a canine model of coronary constriction?
Population
29 anesthetized beagle dogs with partially constricted left circumflex coronary artery.
Comparison
Thromboxane synthetase inhibitors 20 mg/Kg… vs Baseline control cycle length.
Design
Preclinical
Follow-up
Acute observation (up to a few hours)
Authors
Loading...
May attenuate cyclical coronary flow reductions in canine models; leaves open translation to human coronary syndromes.
Does thromboxane synthetase inhibition prevent cyclical reduction of coronary blood flow in a canine model of coronary constriction?
Absolute Event Rate: 104% vs 10%
p-value: p=<0.01
Thromboxane A2 acts as an accelerator in cyclical reduction of coronary flow induced by constriction, as its inhibition eliminates these flow reductions in a canine model.
Uchida et al. (1981) studied Cyclical reduction of coronary blood flow (n=29). Thromboxane synthetase inhibitors (OKY 046 and OKY 1580) vs. Pre-injection control cycle length was evaluated on Reappearance time of cyclical reduction of coronary blood flow (min) (p=<0.01). Intravenous injection of thromboxane synthetase inhibitors OKY 046 and OKY 1580 significantly prolonged the reappearance time of cyclical reduction of coronary blood flow in dogs (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: